{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06287918",
            "orgStudyIdInfo": {
                "id": "3HP-2827-101"
            },
            "organization": {
                "fullName": "3H (Suzhou) Pharmaceuticals Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations",
            "officialTitle": "A First-in-human, Open-label, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-first-in-human-study-of-in-patients-with-unresectable-or-metastatic-solid-tumors-with-alterations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-22",
            "studyFirstSubmitQcDate": "2024-02-28",
            "studyFirstPostDateStruct": {
                "date": "2024-03-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "3H (Suzhou) Pharmaceuticals Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II)."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumors With FGFR2 Alterations, Adult"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 130,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Stage I - dose escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Dose escalation of 3HP-2827 in patients with advanced solid tumors.",
                    "interventionNames": [
                        "Drug: 3HP-2827"
                    ]
                },
                {
                    "label": "Stage II - expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Expansion evaluating the recommended dose and schedule of 3HP-2827 identified from Stage I.",
                    "interventionNames": [
                        "Drug: 3HP-2827"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "3HP-2827",
                    "description": "3HP-2827 will be administered orally once daily in 28-day cycles.",
                    "armGroupLabels": [
                        "Stage I - dose escalation",
                        "Stage II - expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Dose Escalation Stage- incidence of adverse events (AEs)",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Dose Escalation Stage- incidence of dose-limiting toxicities (DLTs)",
                    "timeFrame": "Days 1-28 of Cycle 1 (a cycle is 28 days)"
                },
                {
                    "measure": "Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted Vital Signs",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Dose Escalation Stage -Percentage of Participants With Changes From Baseline in Targeted ECG Parameters",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Dose Escalation Stage -determine the maximum tolerated dose (MTD) and/or the recommended dose (RD) for expansion stage or recommended Phase II dose (RP2D) of 3HP-2827",
                    "timeFrame": "Initiation of study drug until study discontinuation, (up to approximately 24 months)"
                },
                {
                    "measure": "Expansion stage -Objective response rate\uff08ORR\uff09",
                    "timeFrame": "Initiation of study drug until disease progression (up to approximately 36 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma Concentration of 3HP-2827 and/or its major metabolites",
                    "timeFrame": "Initiation of study drug until study discontinuation\uff08up to 45 months\uff09"
                },
                {
                    "measure": "Duration of Response (DOR) as assessed by RECIST v1.1",
                    "timeFrame": "Up to 45 months"
                },
                {
                    "measure": "Progression-free survival (PFS) as assessed by RECIST v1.1",
                    "timeFrame": "Up to 45 months"
                },
                {
                    "measure": "Overall survival",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Dose escalation stage - Objective Response Rate (ORR)",
                    "timeFrame": "Up to 45 months"
                },
                {
                    "measure": "Expansion Stage- incidence of adverse events (AEs)",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted Vital Signs",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted Clinical Laboratory Test Results",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                },
                {
                    "measure": "Expansion Stage -Percentage of Participants With Changes From Baseline in Targeted ECG Parameters",
                    "timeFrame": "From baseline up until 28 days after the final dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* The patient is willing and able to provide written informed consent and has the ability to comply with the study protocol\n* Men or women, age \u2265 18 years at the time of signing informed consent.\n* Histologically or cytologically confirmed surgically unresectable, locally advanced, metastatic solid tumor.\n* ECOG score is 0 or 1.\n* An expected survival of \u2265 12 weeks.\n* Evaluable or measurable disease per RECIST v1.1.\n* Adequate organ function, as measured by laboratory values.\n\nExclusion Criteria:\n\n* Active brain metastases.\n* Have other malignancies within the past 3 years.\n* The toxicity from previous anti-tumor treatment has not recovered to \u2264 grade 1.\n* Clinically significant corneal or retinal disease/keratopathy.\n* Clinically significant cardiovascular disorders.\n* Failure to swallow, chronic diarrhea, or presence of other factors affecting drug absorption.\n* Known to be allergic to any study drug or any of its excipients.\n* Any other diseases or clinical laboratory, etc that may affect the interpretation of the results, or renders the patients at high risk from treatment complications.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Shuchao Wu",
                    "role": "CONTACT",
                    "phone": "+86-21-50895559",
                    "email": "shuchao.wu@3hpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic",
                    "city": "Phoenix",
                    "state": "Arizona",
                    "zip": "85054",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.44838,
                        "lon": -112.07404
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}